Newsroom

News

An influenza vaccination causes the body to form antibodies that circulate in the blood, but which are directed against constantly changing virus components. This means that the vaccine must be re-administered each year. Researchers at the Helmholtz Centre for Infection Research (HZI) in Braunschweig have now shown that the antibody-independent, cellular arm of the immune system can also provide immune protection against influenza. The researchers integrated an influenza antigen into cytomegaloviruses (CMV) and triggered a strong response from the T lymphocytes. The special thing about it: The hybrid viruses, when administered via the nose, attract T cells from the bloodstream into the mucous membranes of the respiratory tract. These immune cells are quickly activated when they come into contact with influenza viruses and then act as guards that block the virus at the most common entry point in the body. The results were published in the journal PLoS Pathogens.

01.10.2019

HZI Campus

News

The Centre for Individualised Infection Medicine (CiiM) is continuing to gain structure and establishment is progressing rapidly. Since summer 2019, this has been accompanied by the new dual leadership of CiiM directors Yang Li and Markus Cornberg.

30.09.2019

CiiM

News

For a long time, itaconic acid was only known as a metabolic product of fungi. Its function was unknown, but for decades it has been used industrially for polymer production. In 2013, it was surprisingly discovered as an important metabolic product in the immune system. This newly described role has sparked a search for potential clinical applications. Researchers at the Helmholtz Centre for Infection Research (HZI) and TWINCORE-Centre for Experimental and Clinical Infection Research, jointly founded by the HZI and the Hanover Medical School, have now solved the crystal structure of the itaconic acid-synthesizing enzyme cis-aconitate decarboxylase (CAD). Their findings provide the basis for an improved understanding of itaconic acid synthesis, the evolutionary origin of this important metabolic step, and the role of itaconic acid in the immune system. In particular, the researchers identified naturally occurring and possibly clinically important variations in the human CAD enzyme.

26.09.2019

HZI Campus

TWINCORE

News

Ascenion GmbH, technology transfer partner of the Helmholtz Centre for Infection Research (HZI), announces the take-over of its portfolio company WBC Drug Delivery Technologies (WBC) by Klaria Pharma Holding AB in an all-stock deal. WBC was founded earlier this year to further advance a new drug delivery technology that was co-developed by scientists at the HZI and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a HZI branch. The researchers coated liposomes with invasins, proteins that enable bacteria to penetrate eukaryotic cell membranes. The resulting carrier system combines the safety and versatility of liposomes with the unique capacity of bacteria to invade human cells. It holds strong potential to improve the treatment of many diseases, also intracellular infections caused by pathogens "hiding" in membrane-bound vacuoles.

19.09.2019

HZI Campus

HIPS

News

If you want to protect yourself from the flu, you have to be vaccinated anew every year because the viruses are constantly changing the components to which our immune system responds. Our immune system primarily reacts to the two viral proteins haemagglutinin (HA) and neuraminidase (NA), although it has been shown that today’s vaccines only trigger a weak immune response against neuraminidase in the vaccinated individuals. This is unfortunate, as evidence suggests that sufficient antibodies against NA can be at least as effective against influenza infections as those against haemagglutinin. The researchers now want to make better use of this effect.

05.09.2019

HZI Campus

News

With their project Vaccine for Prevention and Treatment of Trypanosoma cruzi Infection (CRUZIVAX), a consortium of eleven partners coordinated by the Helmholtz Centre for Infection Research has been awarded funding through the European Commission’s Horizon 2020 work programme. The aim of this project is to develop a highly effective, low-cost and easy to administer prophylactic vaccine candidate for Chagas disease, which is caused by the parasite Trypanosoma cruzi (T. cruzi). The vaccine is to be applied as a nasal spray. The project is coordinated by the Vaccinology department of the Helmholtz Centre for Infection Research (HZI) in Braunschweig under the direction of Prof Carlos A. Guzmán. The total funding amounts to more than eight million euros over a period of five years, about two million euros being provided to the HZI.

25.07.2019

HZI Campus

Back to the first page
...
68
69
70
71
...
147

HZI in the media

... ” Seit Mai 2025 im Humanprogramm des Helmholtz-Zentrums für Infektionsforschung (HZI), Dr. Max Kellner-Leiter der jungen ...

25.09.2025

Die heutigen Nachrichten

” (Vico) within the Human program at the Helmholtz Centre for Infection Research (HZI).the‌ Vico group continues to investigate resilience

25.09.2025

World Today News

Forschende des Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz-Zentrums für ...

19.09.2025

Verband Deutscher Biologen e.V.

purposes.

Researchers at the HIRI, a site of the Braunschweig Helmholtz Center for Infection Research (HZI), in cooperation with the Julius

19.09.2025

NewsBreak

... ihr Team vom Helmholtz-Institut für One Health (HIOH) in Greifswald – einem Standort des Helmholtz-Zentrums ...

18.09.2025

Management & Krankenhaus

... der TU Braunschweig, dem Braunschweig Integrated Centre of Systems Biology (BRICS) und dem Helmholtz-Zentrum für ...

15.09.2025

DeutschesGesundheitsPortal

Das Institut ist ein Teil des rennommierten Helmholtz-Zentrums für Infektionsforschung ...

11.09.2025

NDR Norddeutscher Rundfunk

... gearbeitet werden soll. Greifswald (dpa/mv) - In einem eigenen Gebäude sollen Forscher des Helmholtz-Instituts ...

11.09.2025

n-tv

Direktor des Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI) in Würzburg, einem Standort des Braunschweiger Helmholtz- ...

11.09.2025

MTA Dialog

Studie und Hersteller des Prüfpräparats. Das Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) war bei ...

11.09.2025

Kölner News Journal

at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Institute of Molecular Infection Biology (IMIB) in Würzburg has

10.09.2025

Phys.org

Leiter der Abteilung Chemische Biologie am Helmholtz-Zentrum für Infektionsforschung in Braunschweig www.helmholtz-hzi.de ...

10.09.2025

BR Bayerischer Rundfunk

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.